Shree Ganesh Bio-Tech Intrinsic Value

SHREEGANES • Healthcare
Current Stock Price
₹0.61
Primary Intrinsic Value
₹1.52
Market Cap
₹2.4 Cr
+149.2% Upside
Median Value
₹1.52
Value Range
₹1 - ₹2
Assessment
Trading Below Calculated Value
Safety Margin
59.9%

SHREEGANES Valuation Methods Summary

Method Type Intrinsic Value Range Upside/Downside Details
Book Value Method asset ₹1.52 ₹1.37 - ₹1.67 +149.2% Book Value/Share: ₹15.75, P/B: 2.0x
Revenue Multiple Method revenue ₹1.22 ₹1.10 - ₹1.34 +100.0% Revenue/Share: ₹2.00, P/S: 2.0x
Simple DCF (5Y) dcf ₹1.52 ₹1.22 - ₹1.82 +149.2% CF Growth: 15.0%, Discount: 15%
Method Types: Earnings Asset DCF Growth Dividend Conservative

Want to compare with current market value? Check SHREEGANES share price latest .

Valuation Comparison Chart

SHREEGANES Intrinsic Value Analysis

What is the intrinsic value of SHREEGANES?

Based on our comprehensive analysis using 3 different valuation methods, the estimated intrinsic value of Shree Ganesh Bio-Tech (SHREEGANES) is ₹1.52 (median value). With the current market price of ₹0.61, this represents a +149.2% variance from our estimated fair value.

The valuation range spans from ₹1.22 to ₹1.52, indicating ₹1.22 - ₹1.52.

Is SHREEGANES undervalued or overvalued?

Based on our multi-method analysis, Shree Ganesh Bio-Tech (SHREEGANES) appears to be trading below calculated value by approximately 149.2%.

Financial Health Analysis

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Operating Margin -28.0% Industry Standard: 20%+ Below 10% Indicates operational efficiency level
Asset Turnover Ratio 0.12x Industry Standard: 1.0x+ Below 0.5x Measures asset utilization efficiency

Cash Flow Quality Analysis

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2025 ₹-10 Cr ₹-10 Cr Negative Cash Flow 3/10
March 2024 ₹10 Cr ₹5 Cr Positive Free Cash Flow 7/10
March 2023 ₹11 Cr ₹6 Cr Positive Free Cash Flow 8/10
March 2022 ₹4 Cr ₹3 Cr Positive Free Cash Flow 8/10
March 2021 ₹2 Cr ₹1 Cr Positive Free Cash Flow 7/10